Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $12.56 in the prior trading day, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $12.24, down -2.55%. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 2.4 million shares were traded. OCUL stock price reached its highest trading level at $12.63 during the session, while it also had its lowest trading level at $12.01.
Ratios:
Our goal is to gain a better understanding of OCUL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.09. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when Notman Donald sold 1,066 shares for $12.43 per share. The transaction valued at 13,250 led to the insider holds 308,807 shares of the business.
DONALD D NOTMAN JR. bought 1,066 shares of OCUL for $13,245 on Sep 02 ’25. On Aug 25 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,011 shares for $12.04 each. As a result, the insider received 36,252 and left with 204,093 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2129701376 and an Enterprise Value of 1815506560. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.59 while its Price-to-Book (P/B) ratio in mrq is 6.92. Its current Enterprise Value per Revenue stands at 32.04 whereas that against EBITDA is -7.65.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.46, which has changed by 0.41013825 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $13.85, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is -0.38%, while the 200-Day Moving Average is calculated to be 34.17%.
Shares Statistics:
The stock has traded on average 2.27M shares per day over the past 3-months and 2329350 shares per day over the last 10 days, according to various share statistics. A total of 172.93M shares are outstanding, with a floating share count of 145.76M. Insiders hold about 16.23% of the company’s shares, while institutions hold 79.36% stake in the company. Shares short for OCUL as of 1756425600 were 13835161 with a Short Ratio of 6.72, compared to 1753920000 on 12834007. Therefore, it implies a Short% of Shares Outstanding of 13835161 and a Short% of Float of 7.9799999999999995.
Earnings Estimates
The stock of Ocular Therapeutix Inc (OCUL) is currently in the spotlight, with 4.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.33 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.29 and -$1.62 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.37, with 4.0 analysts recommending between -$1.25 and -$1.59.
Revenue Estimates
12 analysts predict $14.57M in revenue for the current quarter. It ranges from a high estimate of $19M to a low estimate of $12.56M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $15.43MFor the next quarter, 12 analysts are estimating revenue of $16.23M. There is a high estimate of $24.6M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.97M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $65.62M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
